Making improvements in life possible - QIAGEN

1

M A G A Z I N : T H E M A L O R E M I P S U M

D A S U N T E R N E H M E N | K O N Z E R N L A G E B E R I C H T | K O N Z E R N A B S C H L U S S | L O R E M I P S U M

Sample & Assay Technologies Sample & Assay Technologies

www.qiagen.com

Company Overview

Sample & Assay Technologies

Making improvements in life possible

4

Extraction, isolation and purification of the mole-cules of life – DNA, RNA and proteins – in reliable, standardized processes.

Wide range of tailor-made applications to make molecular information from biological samples visible and available for interpretation.

SAMPLE T EChnOLOgiES ASSAY TEChnOLOgiESB iOLOgiCAL SAMPLE

C uS TO M E r WO r k fLOW

Molecular Diagnostics ( 47 % of net sales )

Physicians, hospitals and healthcare providers use QIAGEN technologies to save lives and fight disease. Our products support disease prevention such as screening women for risk of cervical cancer; profiling of patients to pinpoint many infectious diseases; personalized healthcare to guide treatment decisions; and point of need testing to provide on-site diagnosis.

Applied Testing ( 6 % of net sales )

Professionals in fields such as human identification and forensics, food testing and veterinary medicine use QIAGEN technologies in commercial applications beyond human healthcare. Our products are helping to solve crimes, secure food supplies and detect potentially devastating livestock diseases.

Pharma ( 21 % of net sales )

Scientists in the pharmaceutical and biotechnology industries look to QIAGEN to advance gene-based drug discovery and development, supporting the creation of new medical breakthroughs.

Academia ( 26 % of net sales )

Researchers at life science laboratories around the world depend on QIAGEN to advance our understanding of the molecular basis of life. Customers include universities and research institutes.

QIAGEN at a glance

Consumable products ( 85 % of sales ) are spe-cialized kits that contain all necessary materials to support the use of sample and / or assay technologies.

Instruments (15 % of sales ) are used with consumables, even enabling customers to fully automate processes from the preparation of clinical samples to delivery of valuable results.

P rO d u C T C AT E g O r i E S

C uS TO M E r C L A S S E S

VALuABLE MOLECuLAr infOrMAT iOn

* Sales figures by product categories and customer classes based on 2010 net sales

Q IAGEN COMPANIES

Americas

QIAGEN North American Holdings, Inc.Germantown l USA

QIAGEN Sciences, Inc.Germantown l USA

QIAGEN Gaithersburg, Inc.Gaithersburg l USA

QIAGEN, Inc.Valencia l USA

QIAGEN, Inc.Frederick l USA

QIAGEN, Inc.Toronto l Canada

QIAGEN Mexico, S. de R.L. de C.V.Mexico City l Mexico

QIAGEN Brasil Ltda.Sao Paulo l Brazil

Europe

QIAGEN N.V.Venlo l The Netherlands

QIAGEN Benelux B.V.Venlo l The Netherlands

QIAGEN Hamburg GmbHHamburg l Germany

QIAGEN GmbHHilden l Germany

QIAGEN Lake Constance GmbHStockach l Germany

QIAGEN AB, ScandinaviaSolna l Sweden

QIAGEN S.r.l.Milan l Italy

ATQ BiyoteknolojiAnkara l Turkey

QIAGEN S.A.Courtaboeuf Cedex l France

QIAGEN Iberia, S.L.Madrid l Spain

QIAGEN AGBasel l Switzerland

QIAGEN Instruments AGHombrechtikon l Switzerland

QIAGEN Ltd.QIAGEN HouseCrawley l United Kingdom

QIAGEN Manchester Ltd.Manchester l United Kingdom

Asia

QIAGEN Hong Kong Ptd. LimitedKowloon l Hong Kong

QIAGEN Singapore Pte. Ltd.Singapore l Singapore

QIAGEN K.K. Tokyo l Japan

QIAGEN China Co., Ltd. Shanghai l China

PG Biotech Co., Ltd.Shenzhen l China

Tiangen Biotech Co., Ltd.Beijing l China

QIAGEN Korea Ltd.SeouL l South Korea

QIAGEN Sdn. Bhd.Kuala Lumpur l Malaysia

QIAGEN India Pvt. Ltd.New Delhi l India

Australia

QIAGEN Pty Ltd.Melbourne l Australia

QIAGEN Companies QIAGEN Distributors and Importers

Toronto

Germantown / Gaithersburg

Frederick

Valencia

Mexico City

London

Manchester

Paris

Singapore

Shanghai

New Delhi

Beijing

Melbourne

Madrid

Venlo

Seoul

Tokyo

Hilden

Shenzhen

Kuala Lumpur

Hong Kong

Hamburg

Milan

Hombrechtikon

Ankara

Copenhagen

Stockach

Oslo

Stockholm

Helsinki

Sao Paulo

QIAGEN around the world

As the innovative market and technology leader, QIAGEN creates Sample & Assay Technologies to unlock valuable molecular information from any biological sample.

Our mission is to enable our customers to achieve outstanding success and breakthroughs in Molecular Diagnostics, Applied Testing, Pharma and Life Sciences. In doing so we make improvements in life possible.

Our commitment to the markets, customers and patients we serve drives our innovation and leadership in all areas where our Sample & Assay Technologies are required.

The exceptional talent, skill and passion of our employees are key to QIAGEN’s excellence, success and value.

22 QIAGEN–Makingimprovementsinlifepossible

Leading a revolution

QIAGENistheworld’sleadingproviderofinnovativeSample&AssayTechnologies.Ourproductsandsystemsareplayingapivotalroleinthemolecularbiologyrevolutionbyempoweringcustomerstotransformrawbiologicalsamplesintovaluablemolecularinformation.

QIAGENtechnologiesallowhealthcareproviderstodetectdiseaseandmaketreatmentdecisions,scientiststoexplorethesecretsoflife,andotherprofessionalstoapplyadvancedtoolsforadiverserangeofneedsthatincludehumanidentification,veterinarymedicineandfoodsafety.

Biologicalsamplescontainmillionsofmolecules,butonlyasmallportionofthismaterialistypicallyofinterestforspecificmedicalorotherapplica-tions.Sampletechnologiesareusedtocollectbio-logicalmaterialsandstabilize,extractandpurifythemoleculeofinterest.Assaytechnologiesarethenusedtoamplifyandenrichthissmallamountofisolatedmaterialtomakeitreadableandreadyfor interpretation.Sample&AssayTechnologiesoperateinahighlysynchronizedmanner.

Advancing the knowledge of life

QIAGENbeganoperationsin1986byintroduc-ingtotheemergingbiotechnologysectoranovelmethodthatstandardizedanddramaticallyaccel-eratedtheextractionandpurificationofnucleicacids–biologicalmoleculessuchasDNA(deoxy-ribonucleicacid)andRNA(ribonucleicacid)thatareessentialforlifeascarriersofgeneticinfor-mation.

Sincetheintroductionofthatfirstready-to-usekit,whichprovidedallthematerialsneededforsimple,efficientandsafepreparationofnucleicacidsinbacteria,QIAGENhasexpandedtobecomethegloballeaderwithabroadofferingofSample&AssayTechnologies,aswellasrelatedautomatedsystems.

Complex Sample Sample Technologies Pure Analyte Assay Technologies

Target detected

NOYES

3QIAGEN–Makingimprovementsinlifepossible 3

86newproductslaunchedin2010

QIAGEN’sEuropeanheadquartersinHilden,Germany.

Ourproductsareusedinvirtuallyallareasofsci-encefocusedonadvancingknowledgeaboutthemolecularbasisoflife.QIAGENhasbecomeatrustedpartnerbyenablingresearcherstoobtainexcitinginsightswithproducts thatareconsid-eredstandardsforqualityandreliability.MorethanonebillionbiologicalsamplesareestimatedtoalreadyhavebeenpreparedoranalyzedusingQIAGENtechnologiesinlaboratoriesaroundtheworld.

Growing through innovation

QIAGENhasleveragedthisleadershippositioninSample&AssayTechnologies tobuilda strongpositioninMolecularDiagnostics.Thecommercialapplicationofmoleculartechnologiesistransform-inghealthcarebyprovidinghighlyspecificgenet-

icinformationtoguidepreventionandtreatmentstrategies.OurproductsalsoareincreasinglyusedinAppliedTesting–areasofmoleculartestingnotrelated to human healthcare or research thatincludehumanidentification(includingforensics),foodandwatersafety,andveterinarytesting.

Withafocusoninnovation,QIAGENnowmarketsmorethan500coreproductsthataredistributedinmanyvariationsandcombinations.Wecontinu-allyintroduceinnovativeproductstoaddressnewmarketopportunitiesorextendthelifeofexistingproductlines.In2010,welaunched86newprod-ucts.Ourobjectiveistoexpandourleadershippositioninallmarketsweserve.


QIAGEN Instruments – Automating Workflows

Ourextensive instrumentportfolio includes therevolutionaryQIAsymphony,thehighly-portableESEQuantTubeScannerand,inthenearfuture,theultra-highthroughputQIAensemble.

Next-generationplatformsmust takedifferenttypesofbiologicalsamples(suchasblood,tissueorsaliva),isolateandpurifytargetedmoleculesinaspecificsequence,andanalyzethesemateri-als reliably and efficiently to provide usefulresults.ThefullyautomatedQIAsymphonyRGQplatformcanprocessallofourinfectiousdiseaseassaysthroughtheintegrationofRotor-GeneQ.Incontrasttoothersystems,QIAsymphonyRGQallowscustomerstousetheirowntests,aswellasQIAGEN test kits,whichareeasy touseand

guaranteethehighestpossibledegreeofaccura-cyandreliability.

The ESEQuant Tube Scanner is expected toemergeasthestandardforPointofNeedtesting–anewsegmentofMolecularDiagnosticswheretechnologyis takenoutof the labandinto thefieldwhereitisneeded.Theportableandcost-effectivedevice,aboutthesizeofanofficetele-phone,usesauniquefluorescentdetectiontech-nologytoidentifymoleculartargetsatthetouchofabutton,yieldingresultsinfiveto15minutes.Thedevicecanbeoperatedwithbatteriesandcantestformultiplepathogensinjustonerun.Testsforpathogenssuchassalmonella,E.coliandinfluen-zavirusesareundercurrentdevelopment,and

QIAGENoffersproprietarysystemsfortheautomationofentireworkflowsinallapplicationareasandcustomersegments.Throughgreaterstandardization,higheraccuracyandreproducibilityofresults–withincreasedefficiency–QIAGENplatformsarehelpingdrivethedisseminationofmoleculartestingtechnologiesinhealthcarearoundtheworld.

5 to 15minutestoresultswithPointofNeedmoleculartesting


QIAensemble / QIAsymphony

AsymptomaticpatientsGoal:Earlydetection

Market needsScreeningmarketMid-highthroughput(QIAsymphony)High-ultra-highthroughput(QIAensemble)

Assay technologiesExamples:HPV,Chlamydia(CT)/Gonorrhoeae(NG),Trichomonas,Vaginosispanel

QIAsymphony

Pre-diagnosedpatientsGoal:Guidetherapy

Market needsSinglepatienttestingLow-midthroughputHighestflexibility

Assay technologiesExamples:KRAS,EGFR,BRAF,PI3K,PathogenGenotyping

QIAsymphony

SymptomaticpatientsGoal:confirm

Market needsSinglepatienttestingMid-highthroughputHighestflexibility

Assay technologiesExamples:CMV,EBV,HBV,HIV,HCV,Influenza

ESEQuant Tube Scanner

NolabreachableGoal:fastresult,onspot

Market needsRapidturnaroundLowthroughputVersatiletests

Assay technologiesExamples:careHPV,HAI,Influenza

prevention

L ABorAtorY-BASeD teStinG

moLecuL Ar DiAGnoSticS – qiAGen’S four “p ” frAmework

point of neeD

portABLe teStinG

profiL inG perSonALizeD heALthcAre

SAMPlE T EChNOlOGIES ASSAY TEChNOlOGIES

QIAGENiscurrentlyworkingtoexpandthisport-folio.QIAGEN’sESEQuantTubeScannerisalsoexpected tomakeamajor contribution to thequickandaccuratedetectionofanimaldiseasessuchasavianflu,smallruminants’plagueandstockyardfever.Earlydetectioncancurtailorpre-ventthespreadoftheseseriousdiseases,minimiz-inghealthandeconomicimpactonhumans.

QIAensembleisQIAGEN’snext-generationsuiteofautomationplatformsforuseinhigh-volumescreening.QIAensembleisbeingdevelopedtoenable customers to increase the speed andimprove theautomationof processinghumanpapillomavirus(HPV)tests.QIAensembleisexpect-edtohandleanexpandingcontentmenu,includ-

ingnewassaysforchlamydiaandgonorrhea,aswellasanext-generationHPVtestunderdevelop-ment.Innovativetestsarealsobeingconsideredforearlydiseasedetection,suchasforcoloncancer.

66 QIAGEN–Makingimprovementsinlifepossible6 QIAGEN–ImplementingprimaryHPVscreening

Theadventofmolecularbiologyhasrevolutionizedthediagnosisandtreatmentofdiseases.Modernanalysesbasedonthedetectionofnucleicacids(DNAandRNA)offerconsiderableadvantagesovertraditionalmethodsofpathogendetectioninhumans.

Molecular Diagnostics

Moleculartestingidentifiesandmeasuresviruses,bacteriaandparasitesmorerapidlyandwithfargreater sensitivityandspecificity.Byunlockingvaluableinformationfrompatients’DNA,RNAandproteins,QIAGEN’sproductsarehelpinghealth-careprofessionalssavelivesandfightdiseases.

ThisnewgenerationofMolecularDiagnosticscanidentifymicroorganisms,cancercells,bacteriaandvirusesbysearchingfortheirspecificnucleicacidsequences–orcancharacterizepreviouslyunknownDNAsequencesrelatedtohumandiseases.Toprovewhetheradiseaseispresentinapatient,theuniquesequenceofthetargetnucleicacidcausingthedis-easemustbeknown,andeitherthesequenceinthesamplemustbeamplified(targetamplification)orthesignalfromtheDNAmustbeamplified(signalamplification)tofacilitatedetection.

QIAGENoffersoneofthebroadestportfoliosofSample&AssayTechnologiesforuseinhealthcare.SuccessinMolecularDiagnosticsdependsontheability toanalyzepurifiednucleicacidsamplesfromavarietyofsamples,includingblood,tissue,bodyfluidsandstool,andonautomatedsystemsthathandlehundredsofsamplesconcurrently.Oth-erkeyfactorsareconvenience,versatility,reliabili-tyandstandardizationofnucleicacidprocessinganddetectionprocedures.

OurgrowthintheMolecularDiagnosticsmarketisbuiltuponfourstrategiesforfightingdisease–Pre-vention,Profiling,PersonalizedHealthcareandPointofNeedtesting–andQIAGENistargetingeachof these fieldswitha rangeofdedicatedproducts.

QIAGEN–Makingimprovementsinlifepossible 7 7QIAGEN–ImplementingprimaryHPVscreening 7

PREVENTION PERSONALIZEDHEALTHCARE

Screeningofnon-symptomaticpatientstodetectrisksforspecificdiseasesdigeneHPVtestisthe“goldstandard”inscreen-ingwomenforHPVvirus(primarycauseofcervicalcancer)

PROFILING

TestingofsymptomaticpatientstodeterminethetypeandseverityofaninfectionMorethan120assaysofferedtoassessviralandbacterialinfectionssuchasHIV,HBV,HCV,ortuberculosis

Testingofpre-diagnosedpatientstoguidetreat-mentdecisionsanduseofmedicinesMorethan20assaysavailableand15R&Dco-developmentprojectsforcompaniondiagnos-ticsunderwaywithpharmaceuticalcompanies

POINTOFNEED

Moleculartestinginsettingswithnolaboratory,particularlyemergingmarketsPioneerinofferingportabledetectionplatformsthatprovidereliableandrapidresults

189

QIAGENREVENuEDEVELOPMENT[$MILLON.]

565

1000

1100

800

600

400

200

02000 2010

MolecularDiagnostics OtherCustomerClasses

522

15


PrEvENtIoN

WomenwaitingforHPvtestsataruralclinicaspartoftheQIAGENcaresKolkataScreeningProject

50,000womentobescreenedbyQIAGENcaresinKolkata

Improving healthcare through early detection

Earlydetectionofdiseasessaveslives.Bycatchingadiseaseinitsearlystages,physicianscanadmin-ister treatmentearlier, leading to improvedout-comes.Earlierdetectionandtreatmentarenotonlybeneficialtothepatientbutalsosavemoneyforhealthcaresystems.

onesignificantapplicationofpreventiveMolecularDiagnosticsisinthefightagainstcervicalcancer–the secondmost commonmalignantdisease inwomen,whichclaimsabout300,000liveseachyear.QIAGEN’sdigeneHPvtestisregardedasthe“goldstandard”intestingforhigh-risktypesofhumanpapillomavirus(HPv),theprimarycauseofcervicalcancer.Withthewidespreadimplementationofcut-ting-edgemoleculartestingtechnologies,cervicalcan-cercouldsoonbecomeadiseaseofthepast.

Likewise,scientificresearchgeared towards thedevelopmentofnovelbiomarkersispavingthewayfornewdiagnosticsenablingtheearlyandreliabledetectionand treatmentofmanyotherdiseasesbeforethemanifestationofsymptoms.QIAGENisstronglycommittedtoadvancingandstrengtheningtheroleofMolecularDiagnosticsinthepreventionofdisease.

Application/Portfolio highlights

• Prevention,especiallyregardingcervicalcan-cer,isanimportantpartoftheQIAGENcaresCorporateSocialresponsibilityprogram

• thecareHPvtest,QIAGEN’scervicalcancerscreen-ingsolutionforuseinlow-resourceregions,hasreceivedtheEuropeanCEmark,enablingdistri-butioninmanydevelopingcountries

• QIAGEN ispartneringwith theChittaranjanNationalCancerInstitute(CNCI)tobringtheben-efitsofcervicalcancerscreeningandHPvtestingto50,00womeninKolkata,Indiaover5years

• QIAGENistheleadingHPvtestproviderintheU.S.–theworld’slargestHPvtestingmarket

• More than75milliondigeneHPvtestshavebeenshippedworldwide

• thedigene HPvtesthasbeenproventobethegoldstandardbymorethan300publishedclinicalstud-iescoveringmorethan1millionwomenworldwide

• QIAGEN’sacquisitionofCellestisbringsexclu-siveaccesstothenovel‘pre-molecular’QuantiF-EroN®technology,initiallyforhigh-sensitivity,earlydetectionoflatenttuberculosis(tB)andlife-threateningCMvvirus

� 9QIAGEN–Makingimprovementsinlifepossible 9

ProFILING

120tests:leadingourindustryinMolecularDiagnostics

Fighting disease with accurate diagnosis

InProfiling,moleculartestsareusedtoconfirmorquantifyadiagnosis in symptomatic individualswhoareatriskofcarryingadisease.Profilingisakeyaspectofdiseasetreatmentandcontroleffortsandisvital toepidemicprevention,monitoringanderadication.

Withmorethan120tests,QIAGENoffersoneofthebroadestportfoliosencompassingassaysforindividualtargetssuchasinfluenza,HIvorHCvviruses,aswellasmultiplexingassaysthattestforseveraldifferentpathogensinasinglerun.IntheareaofProfiling,moleculartestingofferssignifi-cantadvantagesovertraditionalmethods,provid-ingfasterandmoreaccurateresults.thisiscriti-calbecauseanincorrectorlatediagnosiscanbethedifferencebetweenlifeanddeath.

Growth Strategy

ourQIAsymphonyrGQplatformhasthepoten-tialtoplayacriticalroleindisseminatingMolec-ularDiagnosticsacross thehealthcaremarket.thisrobustplatformaddressesacriticalneedforbroadtestingcapabilitiesatefficientcosts.WeintendtofurtherbroadenourmenuofapprovedassaysforuseonQIAsymphonyrGQ.


• QIAGEN’snext-generationcareHCvtestforhep-atitisCvirus,thefirstofthenewcareproductlinebeingdevelopedandproducedinChina,hasreceivedapprovalfromtheStateFoodandDrugAdministration

• QIAsymphonyrGQ,thelatestexpansionofthisautomationplatform,waslaunchedinlate2010withtheadditionofthe“rotor-GeneQ”real-timePCrdetectiontechnology

• QIAGENgainedaccesstoimportantHIvandHCvassaysforNorthAmericathroughanagree-mentwithAbbott

• the2011acquisitionofIpsogenadds80assaystargeting15biomarkers,includingBCr-ABLandJAK2,establishingQIAGEN’sleadershipinprofil-ingandmonitoringofbloodcancers–plusaprom-isingpipeline


PERSONALIZEDHEALTHCARE

PATIENTSCANRESPONDD IFFERENTLyTOTHESAMEMEDICINE

Anti-Depressants

AsthmaDrugs

DiabetesDrugs

ArthritisDrugs

Alzheimer’sDrugs

CancerDrugs

PERCENTAGEOFTHEPAT IENTPOPuLAT IONFORWHICHAPART ICuLARDRuGINACLASSIS INEFFECT IVE,ONAVERAGE

38%

50%

40%

70%

43%

75%

32approveddiagnosticmarkerspointingthewaytoapersonalizedfuture

Pioneering individual treatment strategies

Peopleoftenreactdifferentlytoadrugbecauseofgeneticvariability.Byusingmolecular testing toknowthegeneticmakeupofapatient,doctorscanbetterpredictandmonitorindividualresponsestoadrug–leadingtosaferandmoreeffectivetherapies.

QIAGENisthegloballeaderincompaniondiag-nosticsforPersonalizedHealthcare,withmorethan20molecularassayscommercializedinselectedmarkets,includingEurope,and15projectsunderwaywithpharmaceuticalcompanies todevelopteststhatguidetreatmentdecisions.

Personalizedmedicinewill haveamonumentalimpactonthefutureofhealthcareworldwide.Theu.S. Food and Drug Administration (FDA) hasalready identified32differentdiagnostic targetmarkersinthecontextofapproveddruglabels.Asthisnumberisexpectedtogrowrapidly,newmolec-ulartechnologieswillbedevelopedtomoreaccu-ratelygaugetheefficacyandsafetyofdrugsinindi-vidualpatients,aswellastoreducetherisksforpharmaceuticalcompaniesintheclinicaltrialstage–all leadingtomorespecificandsaferdrugs.QIAGENistakingaleadershiproleindrivingthisgrowth.


• ThePersonalizedHealthcareportfolioincludesaKRAStesttohelpdeterminethesafetyandeffec-tivenessofso-calledEGFRtherapiesforpatientsfacingcolorectalcancertreatments

• QIAGENalsooffersproductstargetingthecan-cerbiomarkersBRAF (skin, lungand thyroidcancer),EGFR(non-smallcelllungcancerandothersolidtumors)andPI3K(intestine,breast,liver,lung,CNSandgenitourinarycancers)

• TheIpsogenacquisitionaddsassayswithsignif-icantpotentialascompaniondiagnostictestsforuseindeterminingandguidingtreatmentdeci-sionsforpatientswithbreastandvariousbloodcancers


POINTOFNEED

Bringing the lab to the patient

MolecularDiagnosticshasonlybeguntomoveout-sidethelaboratory.QIAGENissettingthestand-ardfornewapplicationsinemergencyhealthcareandotherclinical settings that require fast turn-aroundtimesorhavenoaccesstolabinfrastructure.

PointofNeedtechnologyiscriticaltothewide-spreaddisseminationofMolecularDiagnostics.QIAGEN’sproprietaryESEdeviceishighlyafford-able,canprocessawiderangeofcrudesamplesandproducesresults infive to15minutes.Thisinexpensive,portable,rapidtime-to-resulttechnol-ogywillbringtheadvantagesofMolecularDiag-nosticstoareaswhereitwasnotpreviouslyviable.Widespreadaccesstorapidandaccuratediagno-sisofdiseasewillhelp to save livesanddrivedowncostsinallcornersoftheworld.


• ApplicationareasofthistechnologyincludehealthcareandAppliedTesting(e.g.,veteri-nary,foodandenvironmentaltesting)

• CompatibleassaysthatmightbedevelopedforthisplatformincludetestsforpathogenssuchasSalmonellaandE.colibacteriaaswellasinfluenzaviruses

QIAGEN’sESEQuantTubeScannerPointofNeeddevicebringsmoleculardiagnostictestingtothefieldwhereveritisneeded.


Applied Testing

Theuseofmoleculartestingforapplicationssuchasfightinganimaldiseases,improvingfoodsafetyandforensicsisarathernewbutrapidlygrowingmarketsegment.

QIAGENisdrivingdisseminationinAppliedTesting–ourtermfortheuseofmoleculartechnologiesout-sideofhumanhealthcareandresearchapplications–bydeployingPointofNeedtechnologytoenablecutting-edgemoleculartestinginthefield,forexam-pleatfarmsorfoodproductionfacilities.

Testingtoensurefoodsafety,whetheratthefarmorfartheralonginthefoodsupplychain,isbecomingincreasinglyimportanttomanufacturersandgovern-mentagencies,giventheglobalizationofproductflowsandtherisingnumberofscandals.QIAGENcurrentlyoffers30testsbasedonPCR(polymerasechainreaction)technologyforthedetectionofbacte-rialandviralpathogens,allergens,geneticallymodi-fiedorganismsandotherpollutantsinfood.

Thevalueofgenetic“fingerprinting”alsohasbeendemonstrated incriminal investigations involvingDNAanalysis.DNAtestingisanessentialtoolfor

modernforensics,immigrationandbordercontrol,paternityassignment,andotherhumanidentityappli-cations.QIAGENoffersawiderangeofnucleicacidpurificationproductsandmoleculartestingproce-duresforapplicationssuchas:

• Evidencegivenincriminaltrials(e.g.,theO.J.Simpsoncase)

• Identificationofvictims(e.g.,theIndianOceantsunamidisasterin2004ormassgravessuchastheonecontaininggenocidevictimsinSrebrenica,formeryugoslavia)

• Lineage analysis (e.g.,Neanderthal DNA orMozart’sskull)

• Thegenotypingofhorses(e.g.,u.K.studbook)orofwinebarrels(toensurecorrectoriginofoakwood)


NEWAPPLICATIONSFOR

MOLECuLARTESTING

AppliedTestingrepresentsmoleculartestingmar-ketsnotrelatedtohumanhealthcareandaca-demicorpharmaceuticalresearch.Thissegmentinvolveshumanidentificationandforensics,aswellasveterinaryandfoodtesting.

Customersincludelawenforcementagenciesandgovernmentalprotectionlaboratories,animalhealthorganizationsandveterinarytestinglabo-ratories,foodsafetybodiesandlargefoodmakersaswellasmanyprivateandgovernmentallabo-ratories.

QIAGENsupportstheentirelaboratorywork-flowsofthesecustomers,frominitialsamplepreparationtofinalresult,basedonthesededi-catedassayportfolios:

• investigatorforhumanIDandforensics

•mericonforfoodtesting

•cadorforveterinarytesting

QIAGEN’sAppliedTestingportfolioincludes:

• HumanIDandforensicsteststhatenabletheanalysisofheavilydamagedtracesusingnovelgenomicmarkers

• Foodtestingassaysthatallowthedetectionofpathogens,geneticallymodifiedorganisms,allergensandothercontaminants

• Veterinarytestingproductsforthecontainmentofwidespreadlivestockdiseasessuchasblue-tongueandBVDV

Molecular technologiesaredisseminating ineverydaylife.Standardizationandautomationoflaboratoryworkflowsaremakingadvancedmethodsmoreefficient,reliableandeasytouseforagrowingvarietyofapplications.

QIAGENisattheforefrontofofferingautomatedplatformsthatcoverentireworkflowsandaddressdifferentprocessingcapacitydemands.Wehavebuiltabroadmenuofassaysandcontinuetoaddnewproductstoourdedicatedassayportfolios.

Weareexploringopportunitiestoexpandtheuse of our portable testing platforms and todevelopnovelapplicationsinareassuchasbio-securityandagriculturaltesting.

GROWTHSTRATEGyPORTFOLIOHIGHLIGHTS

2010SALESDISTRIBuTION

ANDGROWTHRATES

30%HumanID(>+15%)

30%Veterinary(>+15%)

40%Food&Other(>+40%)

Source:QIAGENestimates


Pharma

QIAGENSample&AssayTechnologiesareadvancingR&Dachievementatmanyoftheworld’sleadingpharmaceuticalandbiotechnologycompanies.Drugdiscoveryanddevelopmenteffortsincreasinglyemploygenomicinformation,bothtoguideresearchindiseasesandtodifferentiatepatientpopulationsmostlikelytorespondtoparticulartherapies.ApproximatelyhalfofQIAGENsalesinthePharmacustomerclasssupportresearch,whiletheremaininghalfsupportclinicaldevelopment.

Ourproductsmake it possible for Pharma re-searchersto:

• Identifygenesthatparticipateintheemergenceofdiseases

• Studythefunctionsandinteractionsofgenes(orproteins)inentirebiologicalpathways

• Identifyandevaluatetherapeutictargetmoleculesandsuitableactiveagentcandidates

• Identifyandvalidatepotentialbiomarkersthatprovideinformationabout thestatusofadis-ease,orapatient’sgeneticprofileandprobableresponsetoadrug

• AutomateR&Dlaboratoryprocesses,fromsam-plepreparationtoanalyticalresult

Asnewdrugsarecommercialized,testingtechnolo-giesdevelopedinparallelcanmovefromPharmaR&Dinto themarketascompaniondiagnostics.Healthcareprofessionalsthencancustomizetreat-mentsbytestingforbiomarkersthathelpdeterminethesafetyandefficacyprofilesofdrugsinindividu-alpatients,achievingthebestpossibleresultsandavoidingunnecessarytreatments.Suchtestsalsomake itpossible to speedupclinical trialsandreducetheriskoffailure.Todate,QIAGENSam-ple&AssayTechnologieshavebeenputtouseinmorethan1,000clinicaltrials.

1,000clinicaltrialsrelyingonQIAGENtechnologies


QIAGENprovidesadvancedtechnologiesforallstagesofdrugresearchanddevelopment.Wefacilitatetheanalysisofdiseasepathwaysanddiscoveryofdrugtargets.Ourtechnologiesalsohelptoidentifyandvalidatebiomarkers,whichenhancetheprospectsforsuccessinclinicaltrials.

Ourcustomizedproblem-solvingapproachandexpertisearehelpingPharmaceuticalcustomersdevelopbetterandsaferdrugsmorequickly.Astheindustry’sstructurecontinuestochange,par-ticularlythroughconsolidationofmajorpharma-ceuticalcompanies,QIAGENissupportingthesecustomersinimprovingR&Dproductivity.AnotherkeygrowthareaistheincreasingroleofcontractresearchandserviceorganizationsinPharmaR&D.

Wealsocontinuetopioneernewtechnologies,suchastheincreasinglyimportantuseofmiRNAanalysisindrugsafetyassessment.

QIAGEN’sPharmaportfolioincludes:

• ResearchPCRassaypanelsthatcanhelpex-ploreandanalyzeentirebiologicalpathwaysincellsignalinganddiseasessuchascancer,cardiovasculardisordersandAlzheimer’s

• DevelopmentBiomarkersfortargetvalidationandstratificationofpatientsinclinicaltrials.Someofthesebiomarkerscouldbecomemolec-ulartestscommercializedforuseascompaniondiagnosticswithnewmedicines

QIAGENsupportsgene-baseddrugdiscoveryanddevelopment,includingthedevelopmentofcompaniondiagnosticteststhatcanevolveintocommercializedproducts.

Customersincludelargepharmaceuticalcompa-nies,contractresearchandserviceorganiza-tions,andincreasinglysmallerpharmaceuticalandbiotechnologycompanies.

QIAGENofferscompleteworkflowsolutionscov-eringtheentireR&Dcontinuum,fromearly-stageresearchthatincludesidentifyingdrugtargetsandpotentialbiomarkers,throughclinicaldevel-opmentandstratificationofpatientsbasedongeneticinformation.

PORTFOLIOHIGHLIGHTS

HELPINGTOCREATE

BETTERANDSAFERDRuGS

GROWTHSTRATEGy

BIOMARKERSINTRIALS

0

300

250

200

150

100

50

280

2003 2004 2005 2006 2007 2008 2009

NumberofTrials

ClinicalR&Dtrialsincreasinglyusinggeneticbiomarkers

Source:QIAGENanalysisofClinicaltrials.govdata


Academia

QIAGENhasbeenfirmlyrootedintheacademicmarketsinceourestablishmentin1984.ThefirstfocusofQIAGENwasonrevolutionizingthetime-consumingextractionandpuri-ficationofnucleicacids,andourtechnologieshavesmoothedthewaytorapidprogressinmolecularbiology.

QIAGENiscontinuingthetraditiontodaybywork-inghand-in-handwithleadingresearchscientistsindevelopingandimplementinginnovativemolecularsamplepreparationandtestingtechnologiesthatfacilitatenewscientificbreakthroughs.

QIAGEN’sadvancedSample&Assay TechnologiesenablescientistsinAcademiatoachievecomparableandmoreexactresultsforsophisticatedresearch.Manyofthe“greatestbrains”inthelifesciences–includingthe2006and2008winnersoftheNobelPrizeinMed-icine,aswellasinstitutionssuchastheu.S.NationalInstitutesofHealth(NIH),theSmithsonianInstitutionandrenowneduniversitiesandlaboratories–relyonQIAGENproductstogainnewinsightsintothemolec-ularbasicsoflife.

Breakthroughsinlifescienceresearchmadepossi-blebyQIAGENtechnologyincludemicroRNAs,ormiRNAs–aclassofnucleicacidsthatareimportantincontrollinggeneactivityinthehumanbody.Inresearchlabsaroundtheworld,scientistsarepursu-ingthequestionofwhatrolemiRNAmoleculesplayindiseasessuchascancer,Alzheimer’s,hepatitisC,heart failureandschizophrenia.EarlysuccessespointtogreatfuturepromiseinmiRNAs.

WorkingwithAcademiasupportsourpresenceincommercialmarketsbecauseuniversityresearch-ersoftenhelpdevelopspecifictechnologiesandcontributetoscientificpublicationsthatvalidateQIAGENapplications.

70 %ofglobalsamplepreparationmarket


SCIENTIFICPRESENCE

AdvancedtechnologiesfromQIAGENarehelpingscientists inacademicresearchachievebreak-throughstobetterunderstandthemolecularbasicsoflife.Ourproductsprovideresearcherswithcon-fidenceinthequalityandcomparabilityofresults.

Customersincludelifesciencelaboratoriesatmostoftheworld’spublicandprivateresearchinstitutesaswellasuniversities.

QIAGENisdeeplyrootedinlifescienceresearchandpartnerscloselywithscientiststounderstandtheirneeds. InnovationinAcademiasets thepaceforfuturecommercialdevelopments,keep-ingusattheforefrontofbreakthroughsforallofourcustomers.

Theacademicmarket,sustainedbythecommit-mentofmanycountriestothepursuitofresearchandinnovation,offersmanyopportunitiesforlong-termgrowthandisanchoredbyourtechnologyleadershipandstrongrelationshipswithcustomers.Buildingonourleadershipinsamplepreparationtechnologies,QIAGENisincreasinglyprovidinginnovationsinassaytechnologiesandaddress-ingbreakthroughtopicsinresearch.WearealsoaddressingthevibrantresearchsectorintheemergingmarketsofAsiaandLatinAmerica.Asmanyacademiclaboratoriesstrivetoimproveefficiencyamidchallengingeconomicconditions,wearealsoexploringhowourautomationplat-formscouldhelpscientistsmorerapidlyachievepreciseresearchresults.

GROWTHSTRATEGy

QIAGENsolutionsforLifeScience/Academiainclude:

•PyrosequencingAnext-generationsequence-baseddetectiontechnologyforabroadrangeofapplicationsincludingepigeneticresearch

•RNAinterferenceAscientificmethodforpre-ventingthesynthesisofspecificproteinsincellsbyblockingthecorrespondinggenes.RNAiiswidelyusedinresearchtodeterminethefunctionofgenesandtoidentifypotentialdrugtargets

PORTFOLIOHIGHLIGHTS

HELPINGSCIENTISTS

ACHIEVEBREAKTHROuGHS

1995 2000 2005 2010

25,000

20,000

15,000

10,000

5000

30,000 28,433

0

NumberofQIAGENReferencesIncreasingpresenceofQIAGENinscientificpublicationsSource:QIAGENsurveyofvariouspublications


Creating sustainable workplaces and societies

QIAGENfollowsacomprehensiveapproachtosustainability,aimingtoreducetheenvironmen-talimpactofourbusiness,promotehealthyandhigh-performanceworkplacesthatenablebothprofessionalandpersonaldevelopment,drivelong-termgrowth,andhelpsocietiesacrosstheglobelivebetterlives.

4,500gallonsofwaterperyearsaved

Green development

Protecting the environment, health and safetythroughourproductshasalwaysbeenahallmarkofQIAGEN.Overtheyears,QIAGENhascontributedsignificantlytothereplacementoftoxicelementsinsamplepreparationprocedures.

Greeninitiativesaregroupedintotheareasofener-gysavings,paperreduction,packagingandwastereduction,greenbuildings,waterconsumptionandtransportation.Asaresultofourcommitment toenvironmentallysustainabledevelopment,wehavereducedemissionssignificantly.

• In2010,morethan200tonsofCO2weresaved

• Ouru.S.productionfacilitysavesmorethan4.5milliongallonsofpotablewaterperyear

• IntheunitedStates,theproportionofpost-con-sumer waste paper used in production hasincreasedto75%

QIAGEN’sExecutiveCommitteehasappointedaglobalEHScoordinatorwhoconstantlymanagesandmonitorstheprogressofemissionreductionsandim-provementsinemployees’occupationalhealthstatus.

Economic progress

Onlyanorganizationthatiseconomicallysustain-ablecanmakeimprovementsinlifepossibleinthelongrun.TheeconomiccontributionofQIAGENgoesfarbeyondcreatingshareholdervalue–ourbusinesshasacatalyticimpactlocallyandgloballybyhelpingtocreatejobs,stimulatinglocaleconomiesandcontributingtothefundingofpublicservices.

QIAGEN’snewR&DcenterinHilden,GermanywillbecertifiedundertheuSGreenCouncil’sLEEDprogram,theonlyglobalstandardforsustainablebuildings


1,500,000HPVtestsdonatedsavingupto2,400lives

Economicprogressinitiativesaregroupedintotheareasoftraininganddevelopment,businessdevel-opment,innovationmanagement,brandmanage-mentandcorporategovernance.Throughthiscom-mitmentwehaveestablishedtheQIAGENexecutiveMBAbusinessintegrationprogram,ManagementCampusleadershipprogram,andcomprehensivecompensationandcomplianceinfrastructures.

Corporate citizenship

AtQIAGENsustainabilityisakeyaspectofourcor-poratemissiontomakeimprovementsinthequalityoflife.Webelieveitisourresponsibilitytoprovideallpeopleuniversalandequalaccesstoourhealth-caresolutions.ThismeansfacilitatingaccesstoourlifesavingSample&AssayTechnologiesforpeoplearoundtheworld.

QIAGENcares is our comprehensiveCorporateSocialResponsibilityprogram–anumbrellaforthesupportofinitiativesthathelpimprovelivesbyaid-inginthefightagainstdiseasesinwhichQIAGENproductscanplayanimportantrole.

• In2009,QIAGENlaunchedadonationprogramconsistingof1.5millionHPVteststobringcervi-calcancerscreeningtodevelopingcountries

• Alsoin2009,QIAGENjoinedhandswiththeChittaranjanNationalCancerInstitute(CNCI)toprovidefreecervicalcancerscreeningto50,000womeninruralareassurroundingKolkata,India

• AcollaborationbetweenQIAGEN,MerckandtheRepublicofRwandawaslaunchedin2011toimplementacervicalcancerpreventionprogramconsistingoftestingandvaccinationsforwomenandgirlsinRwanda.underthisthree-yearpro-gram,RwandawillbethefirstcountryinAfricato offer a national prevention program that

includes themost advanced vaccinationandscreeningtoolstoprotectwomenfromcervicalcancerandHPV

QIAGENalsohasasponsoringpolicythatdefinestheselectionprocessfordonationsandsponsorshipsoflocalinitiativestosupporthealth,culturalandsocialprograms.

• SponsoringactivitiesincludecooperationwiththeInternationalCommissiononMissingPersons(ICMP)fortheidentificationofpeoplemissingfromthewar inSrebrenica (Bosnia in1995).ThankstoQIAGENtechnologies,thescientistsatICMPareabletoextractDNAfromeverysampletheyhave–evendegradedbonefragments–andgivethousandsofvictimstheiridentitiesback

• AnotherexampleisQIAGEN’ssupportofscientif-icexpeditionstoMountEverestbytheuniversityofPennsylvaniaaimingtodevelopnovelmolec-ulartestsforgenedoping


Inspiring people to make a difference

Theskills,knowledge,dedicationandpassionofourpeoplearecriticalforthesuccessofQIAGEN.Wewanttorecruit,supportandretainthebestemployees,offeringperformance-basedcompensation,developmentopportunities,andbalancebetweenworkandfamilylife.Wearecommittedtodiversityinourteams,reflectingthevariedbackgroundsofourbusinesspartners.

3,700full -timeemployees:makingimprovementsinlifepossible

Corporate culture

AtQIAGEN,werecognizethatavibrantcorporatecultureiskeytothesustainedgrowthofourbusi-ness.AsQIAGENstrivestomakeimprovementsinlifepossible,weareconstantlyworkingtofosteraculturethatencouragesinnovationandreliesonval-uessuchashonesty,respectandfriendliness.

QIAGEN’scorporatecultureisdefinedbyour3I’sconcept:• Identity–Ourvaluesformthebasisofourbusi-

nesssuccess.

• Inspire–Ourleadershipstyletransmitsourvaluesandinspiresouremployees.

• Impact–Ourvalue-basedactionmakesthedif-ference.

WebelieveQIAGEN’sDNA(Identity)isthebasisforourguidingprinciplesofleadership(Inspire)andforouractionsasQIAGENemployees(Impact).

Driving innovation

AstheleadingglobalproviderofSample&AssayTechnologies,weknowtheimportanceofinnova-tion.Onlythroughstrongcommitmenttoinnovationcanwemaintainourleadershippositionandcon-tinue tomake improvements in lifepossible.AtQIAGEN,ourpeopleandculturedrivetheperfor-manceofouraward-winninginnovation.Ourmainsuccessfactoristhatweplacetheselection,devel-opmentandencouragementofemployeesatthecenterofoursystem.Theobjectiveofencouraginginnovationisclearlymappedoutinallofourrele-vantpersonnelprocesses.


Our hR programs

AtQIAGEN,werecognizethatgrowingemployeeswithexceptionaltalents,skillsandpassionarekeytoourlong-termsuccessandcorporatevalue.Tosupportthepersonalandprofessionaldevelopmentofallofouremployees,QIAGENoffersacompre-hensiveportfoliooftraininganddevelopmentcours-es focusingondevelopingbasic competencies,interpersonalskillsandmanagementskills.

Training and retention

QIAGENviewsemployeedevelopmentasaninte-gralsuccessfactorincreatinglastingvalueforourcustomers, patients, colleagues, partners andshareholders.OurglobalPerformanceEnhance-mentSystem(PES)createsaclearframeworkforregular,one-on-onereviewsessionsinwhichman-agersdiscusscareerdevelopmenttopicswitheachindividual.Thesesessionsincludediscussionsofgoalsandtheirachievement,trainingneedsandinterests,careerplanning,organizationaldevelop-ment,andtheresultsofregular“180°surveys.”Professionaltraininganddevelopmentarepartofan ongoing cycle emphasizing participation,reviewandfollow-upforthecareergrowthofeachemployee.

Management campus (MC)

Toensuretheongoingdevelopmentoffutureman-agementgenerations,QIAGENhasdesignedaManagementCampusprogramintwocomponents.MCIacceleratesthecareersofourprofessionalsbyprovidinginsightsintomajormanagementtopicswhilefocusingonindividualdevelopmentandbusi-ness-relatedinnovativeactions.MCIIisaseniorexecutiveprogramdesignedtoinvestintheskillsetsofQIAGEN’sseniormanagers.

Executive MBA program

To support our future growth, QIAGEN offersemployees theopportunity toparticipate in theQIAGENExecutiveMBABusinessIntegrationPro-gramincooperationwiththeuniversityofWürz-burg,Germany.Theprogramexposesprofessionalstoawiderangeofmanagementskillsandknowl-edgeneededforanexecutivecareerintheindustry–andatQIAGEN.Participantsstudyinaninterna-tionalenvironmentwithcolleaguesfromaroundtheworld.TwomodulesareconductedwithpartnersintheunitedStatesatBostonuniversity inBoston,Massachusetts,andatFloridaGulfCoastuniversi-tyinFortMyers,Florida.

QIAGEN awards:

• “BestInnovator2011”bytheglobalconsultingfirmA.T.Kearney

• 2010WorkplaceExcellenceAwardfromtheAlli-anceforWorkplaceExcellence

• 2010Health&WellnessTrailblazerAwardfromtheAllianceforWorkplaceExcellence

• ̀“TopEmployers2010”Award(Germany)forthesixthyearinarow

• Companyoftheyear2008AwardintheunitedStatesandCanadafromACQMagazine

• QIAGENisrecognizedasoneofthebestplacestoworkinLifeSciencesbyTheScientist,oneofthefield’sleadingmagazines


QIAGENNETSALES,EMPLOyEESANDSTRATEGyDEVELOPMENT

Development of QIAGEN

54

1996

330

158

1999

900

263

2001

1,560

298

2002

1,650

75

1997

600

120

1998

800

Net sales ( $ 1,000 )

0

200

100

300

400

500

700

1,000

600

900

800

1,100

1,200

1984

0

NewR&DsiteinMary-land

QIAGENfounded

Firstkitcommercialized

IPONewyorkIPOFrankfurt

Expansionintoautomation

GMPmanufacturingestablished

1986

0,1

52

Leadershipinindividualplatformtechnologies

PRO

Du

CT

STR

ATE

GY

LeadershipinSample&AssayTechnologies

MA

Rk

ET S

TRA

TEG

Y

Integrateplatformtechnologiesintocompleteworkflows

COMPONENTS WORkFlOWS


QIAGENNETSALES,EMPLOyEESANDSTRATEGyDEVELOPMENT

750

500

250

0

1,000

1,250

1,500

2,000

2,750

1,750

2,500

2,250

3,000

3,250

3,500

3,750

No. of employees

1,010

2009

3,400

893

2008

3,000

649

2007

2,600

351

2003

1,550

380

2004

1,300

398

2005

1,600

465

2006

1,800

1,087

2010

3,600

NewR&DsiteinMary-land

LeaderinPersonalizedHealthcare

QIAsymphonySPlaunch

Firstavianfluassay

LeaderinProfiling

LeaderinPrevention

• Createcustomer-specificsaleschannels• Buildcriticalmassinmoleculardiagnostics

Integrateplatformtechnologiesintocompleteworkflows Developworkflows

Expandmolecularcontentonautomatedworkflows

AuTOMATION MOlECulAR CONTENT

MolecularDiagnostics customerclasscreated:•Prevention•Profiling•PersonalizedHealthcare•PointofNeed


As of December 31

$ 1,000 except per share data 2010 2009 2008 2007 2006

Results

Netsales 1,087,431 1,009,825 892,975 649,774 465,778

Operatingincome 188,537 180,205 145,662 83,133 100,601

Netincome 144,311 137,767 89,033 50,122 70,539

Basicearningspershare 0.62 0.67 0.45 0.30 0.47

Dilutedearningspershare(EPS)1 0.60 0.64 0.44 0.28 0.46

Number of shares

Weightedaveragenumberofcommoncharesusedtocomputebasicnetincomepercommonshare 232,635 206,928 196,804 168,457 149,504

Weightedaveragenumberofcommonsharesusedtocomputedilutednetincomepercommonshare 240,483 213,612 204,259 175,959 153,517

Cash flow

Cashflowfromoperations 250,752 216,995 172,998 84,811 101,479

Capitalexpendituresforproperty,plantandequipment 79,667 52,179 39,448 34,492 28,995

Freecashflow(Cashflowfromoperationslesscapitalexpenditures) 171,085 164,816 133,550 50,319 72,484

CashEPS

(Cashflowfromoperations/weightedaveragenumberofdilutedshares) 0.71 0.77 0.65 0.29 0.47

Balance sheet

Totalassets 3,913,995 3,796,464 2,885,323 2,775,174 1,212,012

Cashandcashequivalents 828,407 825,557 333,313 347,320 430,357

Totallong-termliabilities,includingcurrentportion 1,125,070 1,183,182 1,197,088 1,220,084 536,738

Totalshareholders'equity 2,476,353 2,291,169 1,453,844 1,391,575 566,165

+22%5-yearCAGR 5-yearCAGR

+26%5-yearCAGR

+15%

Key financial figuresQIAGENKEyFIGuRES2010

12010resultsreflectcapitalincreasein2009andcorrespondingchangeinnumberofsharesoutstanding.

NETSALES

$ 1,000

A DJ uS T ED NET INCOME

Excludingacquisition,businessintegrationandrelatedchargesaswellasamortizationofacquiredIPandequity-basedcompensation(SFAS123R)of$14.8millionin2006,$61.4millionin2007,$74.3millionin2008,$61.8millionin2009,and$78.4millionin2010.

$ 1,000

A DJ uS T ED D I LuTEDEARNINGSPERSHARE

Excludingacquisition,businessintegrationandrelatedchargesaswellasamortizationofacquiredIPandequity-basedcompensa-tion(SFAS123R)of$0.10in2006,$0.35in2007,$0.36in2008,$0.29in2009,and$0.33in2010.

$ per share

300,000

200,000

100,000

400,000

500,000

600,000

800,000

700,000

900,000

1,000,000

80,000

60,000

40,000

100,000

120,000

140,000

180,000

160,000

200,000

220,000

0.20

0.10

0.00

0.30

0.40

0.50

0.70

0.60

0.80

0.90

2006 2007 2008 2009 2010 2010 20102006 2007 2008 2009 2006 2007 2008 2009

1,100,000 240,000 1.00

Extraction, isolation and purification of the mole-cules of life – DNA, RNA and proteins – in reliable, standardized processes.

Wide range of tailor-made applications to make molecular information from biological samples visible and available for interpretation.

SAMPLE T EChnOLOgiES ASSAY TEChnOLOgiESB iOLOgiCAL SAMPLE

C uS TO M E r WO r k fLOW

Molecular Diagnostics ( 47 % of net sales )

Physicians, hospitals and healthcare providers use QIAGEN technologies to save lives and fight disease. Our products support disease prevention such as screening women for risk of cervical cancer; profiling of patients to pinpoint many infectious diseases; personalized healthcare to guide treatment decisions; and point of need testing to provide on-site diagnosis.

Applied Testing ( 6 % of net sales )

Professionals in fields such as human identification and forensics, food testing and veterinary medicine use QIAGEN technologies in commercial applications beyond human healthcare. Our products are helping to solve crimes, secure food supplies and detect potentially devastating livestock diseases.

Pharma ( 21 % of net sales )

Scientists in the pharmaceutical and biotechnology industries look to QIAGEN to advance gene-based drug discovery and development, supporting the creation of new medical breakthroughs.

Academia ( 26 % of net sales )

Researchers at life science laboratories around the world depend on QIAGEN to advance our understanding of the molecular basis of life. Customers include universities and research institutes.

QIAGEN at a glance

Consumable products ( 85 % of sales ) are spe-cialized kits that contain all necessary materials to support the use of sample and / or assay technologies.

Instruments (15 % of sales ) are used with consumables, even enabling customers to fully automate processes from the preparation of clinical samples to delivery of valuable results.

P rO d u C T C AT E g O r i E S

C uS TO M E r C L A S S E S

VALuABLE MOLECuLAr infOrMAT iOn

* Sales figures by product categories and customer classes based on 2010 net sales

Q IAGEN COMPANIES

Americas

QIAGEN North American Holdings, Inc.Germantown l USA

QIAGEN Sciences, Inc.Germantown l USA

QIAGEN Gaithersburg, Inc.Gaithersburg l USA

QIAGEN, Inc.Valencia l USA

QIAGEN, Inc.Frederick l USA

QIAGEN, Inc.Toronto l Canada

QIAGEN Mexico, S. de R.L. de C.V.Mexico City l Mexico

QIAGEN Brasil Ltda.Sao Paulo l Brazil

Europe

QIAGEN N.V.Venlo l The Netherlands

QIAGEN Benelux B.V.Venlo l The Netherlands

QIAGEN Hamburg GmbHHamburg l Germany

QIAGEN GmbHHilden l Germany

QIAGEN Lake Constance GmbHStockach l Germany

QIAGEN AB, ScandinaviaSolna l Sweden

QIAGEN S.r.l.Milan l Italy

ATQ BiyoteknolojiAnkara l Turkey

QIAGEN S.A.Courtaboeuf Cedex l France

QIAGEN Iberia, S.L.Madrid l Spain

QIAGEN AGBasel l Switzerland

QIAGEN Instruments AGHombrechtikon l Switzerland

QIAGEN Ltd.QIAGEN HouseCrawley l United Kingdom

QIAGEN Manchester Ltd.Manchester l United Kingdom

Asia

QIAGEN Hong Kong Ptd. LimitedKowloon l Hong Kong

QIAGEN Singapore Pte. Ltd.Singapore l Singapore

QIAGEN K.K. Tokyo l Japan

QIAGEN China Co., Ltd. Shanghai l China

PG Biotech Co., Ltd.Shenzhen l China

Tiangen Biotech Co., Ltd.Beijing l China

QIAGEN Korea Ltd.SeouL l South Korea

QIAGEN Sdn. Bhd.Kuala Lumpur l Malaysia

QIAGEN India Pvt. Ltd.New Delhi l India

QIAGEN Taiwan Co., Ltd.Taipei l Taiwan

Australia

QIAGEN Pty Ltd.Melbourne l Australia

QIAGEN Companies QIAGEN Distributors and Importers

Toronto

Germantown / Gaithersburg

Frederick

Valencia

Mexico City

London

Manchester

Paris

Singapore

Shanghai

New Delhi

Beijing

Melbourne

Madrid

Venlo

Seoul

Tokyo

Hilden

Shenzhen

Kuala Lumpur

Hong Kong

Hamburg

Milan

Hombrechtikon

Ankara

Copenhagen

Stockach

Oslo

Stockholm

Helsinki

Sao Paulo

QIAGEN around the world

2

Sample & Assay Technologies Sample & Assay Technologies

www.qiagen.com

Company Overview

Sample & Assay Technologies

Making improvements in life possible

Making improvements in life possible - QIAGEN

Documents